Novartis, Sandoz Recall 12 Drugs Over Packaging Issues
In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). Billion in 2021, the spin-off would create the biggest generic drugs enterprise in Europe by sales. In February 2022, New York City-based biotechnology firm Cambrian Biopharma announced it had licensed rights to mTOR inhibitor applications from Novartis. By way of our Novartis Access Principles, we are committed to systematically integrating access…